Solara Active Pharma Sciences
SOLARA NSE
Solara Active Pharma Sciences
HealthcareNSE: SOLARA BSE: 541540 Pharmaceuticals & Biotechnology
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹3,371 Cr
Volatility
High Risk
P/E Ratio
-2,081.9
EBITDA
₹193 Cr
Return on Equity
-0.59%
Debt to Equity
0.55
Book Value
₹261.38
52W High
₹749.8
52W Low
₹422
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
4- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -3.27% over past five years.
- Company has a low return on equity of -12.0% over last 3 years.
- Promoters have pledged 37.1% of their holding.
Growth Rate
Revenue Growth
6.42% higher than
3Y
Net Income Growth
—
Cash Flow Change
-28.15% lower than
3Y
ROE
—
ROCE
-32.25% higher than
3Y
EBITDA Margin (Avg.)
-15.53% higher than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 352 | 425 | 212 | 299 | 363 | 347 | 300 | 273 | 319 | 314 | 349 | 387 | 382 |
| Expenses | 333 | 388 | 374 | 290 | 322 | 286 | 243 | 228 | 262 | 279 | 312 | 330 | 320 |
| Operating Profit | 19 | 38 | -162 | 10 | 42 | 61 | 58 | 45 | 57 | 35 | 37 | 58 | 62 |
| OPM % | 5% | 9% | -76% | 3.3% | 12% | 18% | 19% | 17% | 18% | 11% | 11% | 15% | 16% |
| Other Income | 2 | -4 | -62 | -120 | 1 | 0 | 1 | 6 | 1 | 0 | -7 | 6 | 3 |
| Interest | 25 | 24 | 25 | 31 | 31 | 28 | 27 | 29 | 24 | 21 | 22 | 28 | 22 |
| Depreciation | 26 | 26 | 26 | 25 | 25 | 25 | 25 | 24 | 24 | 24 | 26 | 26 | 27 |
| PBT | -29 | -17 | -275 | -167 | -13 | 8 | 8 | -2 | 11 | -10 | -17 | 10 | 16 |
| Tax % | -35% | 0% | 0% | 53% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -19 | -17 | -275 | -255 | -13 | 8 | 8 | -2 | 11 | -10 | -17 | 10 | 16 |
| EPS in Rs | -4.07 | -3.58 | -57.36 | -53.2 | -3.74 | 2.22 | 2.24 | -0.58 | 2.91 | -2.79 | -4.82 | 2.65 | 3.41 |
Profit & Loss
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 521 | 1,387 | 1,322 | 1,617 | 1,268 | 1,444 | 1,289 | 1,284 | 1,369 | 1,431 |
| Expenses | 464 | 1,174 | 1,062 | 1,231 | 1,188 | 1,309 | 1,384 | 1,077 | 1,182 | 1,240 |
| Operating Profit | 57 | 213 | 260 | 386 | 81 | 134 | -95 | 206 | 187 | 192 |
| OPM % | 11% | 15% | 20% | 24% | 6% | 9% | -7% | 16% | 14% | 13% |
| Other Income | 2 | 12 | 27 | 29 | 16 | 22 | -185 | 8 | 0 | 2 |
| Interest | 25 | 82 | 78 | 84 | 75 | 90 | 105 | 115 | 95 | 92 |
| Depreciation | 34 | 83 | 94 | 109 | 112 | 111 | 103 | 99 | 100 | 103 |
| PBT | 0 | 60 | 115 | 222 | -91 | -45 | -488 | 1 | -7 | -2 |
| Tax % | -70% | 1% | 0% | 0% | -36% | -50% | 16% | 0% | 0% | — |
| Net Profit | 0 | 59 | 115 | 221 | -58 | -22 | -567 | 1 | -7 | -2 |
| EPS in Rs | — | 17.3 | 32.01 | 46.22 | -12.11 | -4.62 | -118 | 0.15 | -2.05 | -1.55 |
| Div. Payout % | 0% | 22% | 5% | 11% | 0% | -49% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 25 | 26 | 27 | 36 | 36 | 36 | 36 | 40 | 45 |
| Reserves | 739 | 930 | 1,059 | 1,553 | 1,489 | 1,464 | 898 | 1,054 | 1,208 |
| Borrowings | 633 | 538 | 722 | 621 | 1,037 | 1,013 | 1,012 | 796 | 687 |
| Other Liabilities | 425 | 466 | 346 | 404 | 383 | 386 | 406 | 342 | 393 |
| Total Liabilities | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 | 2,333 |
| Fixed Assets | 1,086 | 1,218 | 1,397 | 1,382 | 1,356 | 1,364 | 1,268 | 1,193 | 1,238 |
| CWIP | 71 | 40 | 40 | 88 | 239 | 238 | 256 | 280 | 205 |
| Investments | 1 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 5 |
| Other Assets | 663 | 701 | 716 | 1,144 | 1,350 | 1,295 | 825 | 757 | 886 |
| Total Assets | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 | 2,333 |
Cash Flow
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Operating | 49 | 166 | 242 | 155 | -242 | 156 | 109 | 213 | 153 |
| Investing | -85 | -113 | -359 | -106 | -243 | -81 | -4 | -37 | -99 |
| Financing | 68 | -23 | 97 | 92 | 334 | -113 | -106 | -180 | -54 |
| Net Cash Flow | 31 | 30 | -20 | 142 | -151 | -38 | 0 | -4 | 1 |
| Free Cash Flow | 14 | 108 | -25 | -16 | -451 | 46 | 69 | 173 | 101 |
| CFO/OP | 92 | 85 | 103 | 49 | -277 | 106 | -113 | 104 | 83 |
Ratios
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 184 | 76 | 63 | 109 | 141 | 136 | 99 | 93 | 117 |
| Inventory Days | 252 | 111 | 170 | 149 | 321 | 258 | 163 | 185 | 170 |
| Days Payable | 420 | 127 | 132 | 156 | 154 | 142 | 142 | 144 | 146 |
| Cash Conversion Cycle | 16 | 60 | 101 | 102 | 308 | 252 | 120 | 134 | 140 |
| Working Capital Days | -124 | -22 | -32 | 16 | 37 | 20 | -128 | -62 | -24 |
| ROCE % | — | 10% | 12% | 15% | 0% | 2% | -9% | 6% | 5% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Solara Active Pharma Sciences insights
70 extracted metrics + investor summaries across FY16–FY27.
Documents
1
Clarification sought from Solara Active Pharma Sciences Ltd
10 Jun - Exchange has sought clarification from Solara Active Pharma Sciences Ltd on June 10, 2026, with reference to Movement in Volume. 10 Jun - Exchange has sought clarification from Solara Active Pharma Sciences Ltd on June 10, 2026, with reference to Movement in Volume.
2
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
10h - Solara Active Pharma Sciences Limited has informed about the Schedule of Investors/Analysts call to be held on Friday, May 15, 2026 at 15.00 IST, to … 10h - Solara Active Pharma Sciences Limited has informed about the Schedule of Investors/Analysts call to be held on Friday, May 15, 2026 at 15.00 IST, to …
3
Board Meeting Intimation for Intimation Regarding Board Meeting Under Regulation 29 Of SEBI (LODR), Regulations, 2015 ('Listing Regulations')
8 May - Board meets May 15, 2026 to approve audited Q4 and FY2026 standalone and consolidated results. 8 May - Board meets May 15, 2026 to approve audited Q4 and FY2026 standalone and consolidated results.
4
Announcement under Regulation 30 (LODR)-Press Release / Media Release
28 Apr - US FDA closed Puducherry facility inspection on Apr 24, 2026 with VAI classification. 28 Apr - US FDA closed Puducherry facility inspection on Apr 24, 2026 with VAI classification.
5
Announcement under Regulation 30 (LODR)-Press Release / Media Release
28 Apr - US FDA closed Puducherry facility inspection on Apr 24, 2026 with VAI classification. 28 Apr - US FDA closed Puducherry facility inspection on Apr 24, 2026 with VAI classification.
Frequently Asked Questions about Solara Active Pharma Sciences
What does Solara Active Pharma Sciences Ltd do?
Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs.[1]
It was formed through demerger of API business from Strides Shasun Ltd (currently named as Stride Pharma Sciences)...
Where is Solara Active Pharma Sciences Ltd (SOLARA) listed?
Solara Active Pharma Sciences Ltd trades as SOLARA on the NSE and under code 541540 on the BSE.
Which sector does Solara Active Pharma Sciences Ltd belong to?
Solara Active Pharma Sciences Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Solara Active Pharma Sciences Ltd?
Solara Active Pharma Sciences Ltd has a market capitalisation of ₹3,371 Cr, which places it in the Small Cap band.
What is the PE ratio of Solara Active Pharma Sciences Ltd?
Solara Active Pharma Sciences Ltd trades at a PE ratio of -2081.90, against a book value of ₹261.38 per share.
What is the 52-week high and low of Solara Active Pharma Sciences Ltd?
Over the last 52 weeks Solara Active Pharma Sciences Ltd has traded between ₹422 and ₹749.8.
Does Solara Active Pharma Sciences Ltd pay dividends?
Solara Active Pharma Sciences Ltd has a dividend yield of 0.42%.
What is the Return on Equity (ROE) of Solara Active Pharma Sciences Ltd?
Solara Active Pharma Sciences Ltd reported a return on equity of -0.59%. Its debt-to-equity ratio is 0.55.
Company Information
Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs.[1] It was formed through demerger of API business from Strides Shasun Ltd (currently named as Stride Pharma Sciences). Subsequently, it also acquired the human API business from Sequent Scientific Ltd during the same time, making it a pure play API company.[2]
Website solara.co.in
CEO Mr. Sandeep Shashikantha Rao M.Sc., PGDM
Employees 1,775
Listed 2018-06-27
Face Value ₹ 10
Issued Size 3,61,71,307
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SOLARA.md for Solara Active Pharma Sciences Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.